EGFR and non-small cell lung carcinoma: In conclusion, platinum rechallenge with paclitaxel‐carboplatin and bevacizumab as a late‐line therapy may be an effective option in patients with nonsquamous NSCLC, regardless of the presence or absence of EGFR mutations.